
A comparative analysis between Goldman Sachs (GS) and Moelis & Company (MC) highlights diverging strategies and growth prospects. While GS, a global IB leader, is refocusing on core businesses after a decline in Q1 2025 IB revenue, MC, an advisory-focused boutique, demonstrates resilience with a 10% CAGR over five years and is poised to benefit from restructuring activity. MC projects a 42.4% earnings growth for 2026, significantly outpacing GS's 13.1%, and offers a higher dividend yield of 4.64% compared to GS's 1.92%.
Goldman Sachs (GS), a global financial services leader, is undergoing a strategic refocus by exiting lower-margin consumer finance, such as its Apple Card partnership, to concentrate on core investment banking (IB) and expand its private credit portfolio, targeting $300 billion by 2030. While GS reported a 24% increase in IB revenues in 2024, a subsequent 8% decline in Q1 2025 and recent downward revisions to its 2025 and 2026 earnings estimates (projected growth of 9.6% and 13.1% respectively) introduce near-term caution, reflected in its Zacks Rank #4 (Sell); the stock trades at a 13.26X forward P/E with a 1.92% dividend yield. In contrast, Moelis & Company (MC), an advisory-focused boutique, has demonstrated resilient performance with a 10% revenue CAGR over the five years to 2024 and continued momentum into Q1 2025, buoyed by global restructuring activity. MC projects significantly higher 2026 earnings growth of 42.4% and revenue growth of 20.9%, offers a more attractive dividend yield of 4.64%, and its estimates remain stable, though it trades at a premium forward P/E of 25.65X and holds a Zacks Rank #3 (Hold). MC's smaller market capitalization ($4.4 billion versus GS's $188.3 billion) and specialized model position it for potential outsized growth, capitalizing on current demand for M&A and restructuring advisory.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment